أمينوغلوتيثيميد (بالإنجليزية: Aminoglutethimide) هو دواء يُستعمل في علاج: * سرطان البروستاتا * سرطان الثدي * متلازمة كوشينغ (ar)
Aminoglutethimide (AG), sold under the brand names Elipten, Cytadren, and Orimeten among others, is a medication which has been used in the treatment of seizures, Cushing's syndrome, breast cancer, and prostate cancer, among other indications. It has also been used by bodybuilders, athletes, and other men for muscle-building and performance- and physique-enhancing purposes. AG is taken by mouth three or four times per day. Side effects of AG include lethargy, somnolence, dizziness, headache, appetite loss, skin rash, hypertension, liver damage, and adrenal insufficiency, among others. AG is both an anticonvulsant and a steroidogenesis inhibitor. In terms of the latter property, it inhibits enzymes such as cholesterol side-chain cleavage enzyme (CYP11A1, P450scc) and aromatase (CYP19A1), thereby inhibiting the conversion of cholesterol into steroid hormones and blocking the production of androgens, estrogens, and glucocorticoids, among other endogenous steroids. As such, AG is an aromatase inhibitor and adrenal steroidogenesis inhibitor, including both an androgen synthesis inhibitor and a corticosteroid synthesis inhibitor. AG was introduced for medical use, as an anticonvulsant, in 1960. It was withdrawn in 1966 due to toxicity. Its steroidogenesis-inhibiting properties were discovered serendipitously and it was subsequently repurposed for use in the treatment of Cushing's syndrome, breast cancer, and prostate cancer from 1969 and thereafter. However, although used in the past, it has mostly been superseded by newer agents with better efficacy and lower toxicity such as ketoconazole, abiraterone acetate, and other aromatase inhibitors. It remains marketed only in a few countries. (en)
L'aminoglutetimide è un farmaco ad azione anti-steroidea. È commercializzato da Novartis come Cytadren. (it)
Aminoglutetimida é um fármaco que inibe a esteroidogênese, sendo indicado para o tratamento da síndrome de Cushing reduzindo o nível do cortisol no organismo. Também é utilizadano tratamento do câncer ósseo doloroso, entre outras indicações. O princípio de ação farmacológico atua na inibição da conversão de colesterol em pregnenolona. Através desse mecanismo inibe a secreção de estrógeno, aldosterona e cortisol. (pt)
Aminoglutetymid – organiczny związek chemiczny z grupy cyklicznych imidów. W organizmach żywych hamuje syntezę wszystkich hormonalnie czynnych steroidów. Aminoglutetymid jest inhibitorem aromatazy. (pl)
أمينوغلوتيثيميد (بالإنجليزية: Aminoglutethimide) هو دواء يُستعمل في علاج: * سرطان البروستاتا * سرطان الثدي * متلازمة كوشينغ (ar)
L'aminoglutetimide è un farmaco ad azione anti-steroidea. È commercializzato da Novartis come Cytadren. (it)
Aminoglutetimida é um fármaco que inibe a esteroidogênese, sendo indicado para o tratamento da síndrome de Cushing reduzindo o nível do cortisol no organismo. Também é utilizadano tratamento do câncer ósseo doloroso, entre outras indicações. O princípio de ação farmacológico atua na inibição da conversão de colesterol em pregnenolona. Através desse mecanismo inibe a secreção de estrógeno, aldosterona e cortisol. (pt)
Aminoglutetymid – organiczny związek chemiczny z grupy cyklicznych imidów. W organizmach żywych hamuje syntezę wszystkich hormonalnie czynnych steroidów. Aminoglutetymid jest inhibitorem aromatazy. (pl)
Aminoglutethimide (AG), sold under the brand names Elipten, Cytadren, and Orimeten among others, is a medication which has been used in the treatment of seizures, Cushing's syndrome, breast cancer, and prostate cancer, among other indications. It has also been used by bodybuilders, athletes, and other men for muscle-building and performance- and physique-enhancing purposes. AG is taken by mouth three or four times per day. (en)